Strongbridge Biopharma plc Announces Presentation at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
July 06 2016 - 7:30AM
Strongbridge Biopharma plc (NASDAQ:SBBP), a global rare disease
biopharmaceutical company focused on the development and
commercialization of novel therapeutic options, today announced
that management will be presenting at Cantor Fitzgerald’s 2nd
Annual Healthcare Conference, taking place July 12-13 at the Le
Parker Meridien in New York City.
Matthew Pauls, president and chief executive officer of
Strongbridge Biopharma, will provide a corporate overview on
Wednesday, July 13 at 2:30 p.m. ET. The presentation will be
webcast live and archived on the “Events & Presentations” page
in the Investor section of the Company’s website at
www.strongbridgebio.com.
About Strongbridge
Biopharma Strongbridge
Biopharma is a global rare disease biopharmaceutical company
focused on the development and commercialization of novel
therapeutic options. Strongbridge’s lead product candidate, COR-003
(levoketoconazole), is a cortisol inhibitor currently being studied
in the global Phase 3 SONICS trial for the treatment of endogenous
Cushing's syndrome. Strongbridge’s rare endocrine disease franchise
also includes COR-005, a next-generation somatostatin analog (SSA)
being investigated for the treatment of acromegaly, with potential
additional applications in Cushing's disease and neuroendocrine
tumors. Both COR-003 and COR-005 have received orphan designation
from the U.S. Food and Drug Administration and
the European Medicines Agency. For more information,
visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
The Trout Group
Marcy Nanus
+1 646-378-2927
mnanus@troutgroup.com
USA
900 Northbrook Drive
Suite 200
Trevose, PA 19053
Tel. +1 610-254-9200
Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2023 to Apr 2024